These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32496211)

  • 1. Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes.
    Foca A; Dhillon A; Lahlali T; Lucifora J; Salvetti A; Rivoire M; Lee A; Durantel D
    Antivir Ther; 2020; 25(3):151-162. PubMed ID: 32496211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
    Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
    Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication.
    Wang WH; Studach LL; Andrisani OM
    Hepatology; 2011 Apr; 53(4):1137-47. PubMed ID: 21480320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
    Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimized RNA interference therapeutics combined with interleukin-2 mRNA for treating hepatitis B virus infection.
    Zai W; Yang M; Jiang K; Guan J; Wang H; Hu K; Huang C; Chen J; Fu W; Zhan C; Yuan Z
    Signal Transduct Target Ther; 2024 Jun; 9(1):150. PubMed ID: 38902241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes.
    Zeng J; Wu D; Hu H; Young JAT; Yan Z; Gao L
    Hepatology; 2020 Dec; 72(6):1935-1948. PubMed ID: 32145089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
    Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
    J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.
    Lahlali T; Berke JM; Vergauwen K; Foca A; Vandyck K; Pauwels F; Zoulim F; Durantel D
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus.
    Isorce N; Testoni B; Locatelli M; Fresquet J; Rivoire M; Luangsay S; Zoulim F; Durantel D
    Antiviral Res; 2016 Jun; 130():36-45. PubMed ID: 26971407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.
    Shi M; Zhao X; Zhang J; Pan S; Yang C; Wei Y; Hu H; Qiao M; Chen D; Zhao X
    Int J Nanomedicine; 2018; 13():6885-6902. PubMed ID: 30498349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
    König A; Yang J; Jo E; Park KHP; Kim H; Than TT; Song X; Qi X; Dai X; Park S; Shum D; Ryu WS; Kim JH; Yoon SK; Park JY; Ahn SH; Han KH; Gerlich WH; Windisch MP
    J Hepatol; 2019 Aug; 71(2):289-300. PubMed ID: 31077792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.
    Xia Y; Carpentier A; Cheng X; Block PD; Zhao Y; Zhang Z; Protzer U; Liang TJ
    J Hepatol; 2017 Mar; 66(3):494-503. PubMed ID: 27746336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
    Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HBV cure: why, how, when?
    Levrero M; Testoni B; Zoulim F
    Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
    Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
    J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
    Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver Carcinogenesis.
    Zhang H; Diab A; Fan H; Mani SK; Hullinger R; Merle P; Andrisani O
    Cancer Res; 2015 Jun; 75(11):2363-74. PubMed ID: 25855382
    [TBL] [Abstract][Full Text] [Related]  

  • 20.  p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
    Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
    Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.